BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 23403638)

  • 1. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
    Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
    Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling.
    Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG
    J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET bromodomain inhibition of MYC-amplified medulloblastoma.
    Bandopadhayay P; Bergthold G; Nguyen B; Schubert S; Gholamin S; Tang Y; Bolin S; Schumacher SE; Zeid R; Masoud S; Yu F; Vue N; Gibson WJ; Paolella BR; Mitra SS; Cheshier SH; Qi J; Liu KW; Wechsler-Reya R; Weiss WA; Swartling FJ; Kieran MW; Bradner JE; Beroukhim R; Cho YJ
    Clin Cancer Res; 2014 Feb; 20(4):912-25. PubMed ID: 24297863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.
    Hogg SJ; Newbold A; Vervoort SJ; Cluse LA; Martin BP; Gregory GP; Lefebure M; Vidacs E; Tothill RW; Bradner JE; Shortt J; Johnstone RW
    Mol Cancer Ther; 2016 Sep; 15(9):2030-41. PubMed ID: 27406984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
    Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
    Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway.
    Wen N; Guo B; Zheng H; Xu L; Liang H; Wang Q; Wang D; Chen X; Zhang S; Li Y; Zhang L
    Int J Oncol; 2019 Oct; 55(4):879-895. PubMed ID: 31485609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.
    Zhu X; Enomoto K; Zhao L; Zhu YJ; Willingham MC; Meltzer P; Qi J; Cheng SY
    Clin Cancer Res; 2017 Jan; 23(2):430-440. PubMed ID: 27440272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
    Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
    Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo.
    Shao Q; Kannan A; Lin Z; Stack BC; Suen JY; Gao L
    Cancer Res; 2014 Dec; 74(23):7090-102. PubMed ID: 25277525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
    Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
    Tolani B; Gopalakrishnan R; Punj V; Matta H; Chaudhary PM
    Oncogene; 2014 May; 33(22):2928-37. PubMed ID: 23792448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.
    Kamijo H; Sugaya M; Takahashi N; Oka T; Miyagaki T; Asano Y; Sato S
    Arch Dermatol Res; 2017 Aug; 309(6):491-497. PubMed ID: 28593508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.
    Ishida CT; Shu C; Halatsch ME; Westhoff MA; Altieri DC; Karpel-Massler G; Siegelin MD
    Oncotarget; 2017 Jun; 8(23):37140-37153. PubMed ID: 28415755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.
    Lockwood WW; Zejnullahu K; Bradner JE; Varmus H
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
    Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
    Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
    Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A
    Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.
    Trabucco SE; Gerstein RM; Evens AM; Bradner JE; Shultz LD; Greiner DL; Zhang H
    Clin Cancer Res; 2015 Jan; 21(1):113-22. PubMed ID: 25009295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.